PCVX
Vaxcyte Inc

739
Loading...
Loading...
News
all
press releases
2 ‘Strong Buy’ Growth Stocks That Could Gain More Than 340%
A volatile market presents the perfect opportunity to grab outstanding stocks at a bargain.
barchart.com·5mo ago
News Placeholder
More News
News Placeholder
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 7, 2025 NEW YORK, Jan. 7, 2025...
PR Newswire·8mo ago
News Placeholder
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's...
Benzinga·1y ago
News Placeholder
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market...
Yahoo! Finance: News·1y ago
News Placeholder
Futures Slide As US Returns From Holiday And Data Deluge Looms
Futures Slide As US Returns From Holiday And Data Deluge Looms US equity futures are trading near session lows, tracking Monday's slide in global markets which sent Chinese stocks to 7...
Zero Hedge·1y ago
News Placeholder
Peering Into Vaxcyte's Recent Short Interest
read more...
Benzinga·1y ago
News Placeholder
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vaxcyte, Inc. (NASDAQ: PCVX)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vaxcyte, Inc. (NASDAQ: PCVX) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of...
PR Newswire·1y ago
News Placeholder
Optimistic Outlook for Vaxcyte's Market Dominance and High Valuation Potential
Leerink Partners analyst David Risinger has reiterated their bullish stance on PCVX stock, giving a Buy rating yesterday. David Risinger has given...
TipRanks Financial Blog·1y ago
News Placeholder
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Globe Newswire·1y ago
News Placeholder
Vaxcyte (PCVX, $66.69) Aroon Indicator entered a Downtrend on April 01, 2024.
For the last three days, A.I.dvisor has detected that PCVX's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Tickeron - Stocks·1y ago

Latest PCVX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.